Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07187908 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Name: Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN — clinical trial record (NCT07187908)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorHenan Cancer Hospital

Started2025-01-01

View on ClinicalTrials.gov ↗

Henan Cancer Hospital

107 trials monitored

See 2 trials at risk

Efbemalenograstim alfa for primary/secondary prevention in patients with solid tumors at high risk for febrile neutropenia (FN) or Intermediate risk of chemotherapy regimens associated with other risk factors in FN

Trial Details

NCT Number	NCT07187908
Lead Sponsor	Henan Cancer Hospital Collaborators: West China Hospital
Conditions	Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
Enrollment	1,076 participants
Start Date	2025-01-01
Primary Completion	2026-10 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2025-09-23